Hjem › Adenokarcinom i spiserøret › Massachusetts
Kliniske studier for Adenokarcinom i spiserøret i Massachusetts
13 studier for Adenokarcinom i spiserøret søker deltakere på steder i Massachusetts.
Byer i Massachusetts
Offisiell studietekst (engelsk)
A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers
- Dana-Farber Cancer Institute, Boston
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 5. okt. 2026 · NCT07544589mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
- Boston Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
- Dana-Farber Cancer Institute at Boston Medical Center - Brighton, Brighton
- og 4 flere
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT05677490A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Dana-Farber Cancer Institute - Chestnut Hill, Newton
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT07090499Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Dana-Farber Cancer Institute, Boston
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 30. sep. 2026 · NCT06324357Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas
- Massachusetts General Hospital, Boston
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 21. sep. 2026 · NCT07546812Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia
- Beth Israel Deaconess Medical Center, Boston
Rekrutterer
Alder 18 til 89 · Alle kjønn · Oppdatert 11. sep. 2026 · NCT05753748Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
- Research Site, Boston
- Research Site, Burlington
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 9. sep. 2026 · NCT07431281A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Boston
- Normunity Investigational Site, Boston
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 18. aug. 2026 · NCT07182149A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- Massachusetts General Hospital, Boston
- Brigham & Women's Hospital, Boston
- Beth Israel Deaconess Medical Center,East Campus Research Pharmacy, Boston
- og 3 flere
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 6. jul. 2026 · NCT04389632Clonal Hematopoiesis Chemotherapy and Radiation Effects Study
- Dana-Farber Cancer Institute, Boston
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 30. jun. 2026 · NCT07675967First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
- Research Site, Boston
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 12. jun. 2026 · NCT07284186Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
- I-Mab Site 1002, Boston
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 14. mai 2026 · NCT07432295Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
- Mass General Hospital, Boston
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 5. mar. 2026 · NCT04900818Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.